INTRODUCTION
Tumour cells need a constant supply of both energy and nitrogen substrates. Glutamine, the most abundant amino acid in the plasma, is described as the main physiological nitrogen vehicle between different mammalian tissues [1] . The presence of a tumour produces great changes in the host glutamine metabolism a few days after tumour transplantation, resulting in an increase in the circulating glutamine [2] . Before being metabolized, glutamine must be transported across both the plasma membrane [3] and the inner mitochondrial membrane [4] , since phosphateactivated glutaminase, the first step in the glutaminolytic process, is loosely anchored to the inner leaflet (on the matrix side) of the mitochondria [5] . Malignant cells transport glutamine at a faster rate than non-malignant cells across their plasmatic membranes by means of Na + -dependent A and ASC amino acid-transport systems [3] , and across the inner mitochondrial membrane by a carrier-mediated system [4] .
Many experimental data provide evidence that phosphateactivated glutaminase (EC 3.5.1.2) is correlated with malignancy in tumours [6, 7] . The enzyme is differentially expressed ; its activity reaches a maximum during exponential growth phase, and the relative abundance of glutaminase mRNA significantly increases as compared with the stationary growth phase [8, 9] . Thus glutaminase activity parallels the levels of poly(A) + RNAs encoding for mitochondrial glutaminase. The enzyme has been isolated to homogeneity from Ehrlich ascites carcinoma ; the tumour enzyme shows kinetic behaviour that resembles kidneytype glutaminase [10, 11] .
The presence of high levels of glutaminase seems to be a common feature of rapidly dividing cells. Nevertheless, neither energy nor biosynthetic requirements can totally explain the very high glutaminolytic flux found in tumours and rapidly dividing cells (see [12, 13] for reviews). Crabtree and Newsholme [14] suggest that active glutaminolysis is needed for preparing cells to Abbreviations used : EATC, Ehrlich ascites tumour cell ; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide. 1 To whom correspondence should be addressed (e-mail fcarrion!uma.es).
ascitic tumour, with a lifespan of 16p1 days, when inoculated with 10( cells\mouse ; on the contrary, animals inoculated with transfected cells up to 2.5 times the cell numbers of control mice did not develop tumours and behaved as healthy animals. The ability to revert the transformed phenotype of antisensetransfected cells confirms the relevance of glutaminase in the transformation process and could provide new ways for the study of gene therapy.
Key words : cancer, cell proliferation, gene expression blockage, glutamine therapy. supply energy or metabolic precursors when required, and consequently cells behave as dissipative systems. In spite of the relevance of glutaminase in cancer growth, studies on this enzyme are scarce.
The present study was undertaken to gain direct evidence on the role of glutaminase in tumour growth and proliferation. Ehrlich ascites carcinoma cells cultured in itro have been transfected by lipofection with the plasmid pcDNA3 containing an antisense 3h-cDNA segment of rat glutaminase that is well conserved in all known glutaminase sequences. If our working hypothesis is correct, that is, that glutaminase is essential for celltransformed phenotype sustenance, the inhibition of glutaminase by producing a glutaminase antisense RNA must result in a decrease in the proliferation rate and other characteristics of the transformed phenotype. The presented results confirm this hypothesis and the relevance of glutaminase in maintaining the malignant phenotype of tumour cells. Furthermore, transfected cells lost their tumourigenic capacity in i o when inoculated in isologous mice.
MATERIALS AND METHODS

Construction of plasmids expressing antisense-RNA glutaminase
Two partial-length rat kidney glutaminase cDNA segments, HindIII (1893)-EcoRI (1614) and EcoRI (3314)-EcoRI (1614), obtained from the pGA104 recombinant plasmid [15] , were subcloned in their antisense orientations behind the cytomegalovirus promoter of the pcDNA3 vector from Invitrogen (San Diego, CA, U.S.A.) by standard recombinant techniques. The resulting constructions were designated pcDNA3-0.28 and pcDNA3-1.7, respectively. The structures of the recombinants were verified by restriction-enzyme digestion of isolated DNA. The 3h-end sequences of 1.7 and 0.28 kb were selected because of the high sequence similarity found amongst cDNAs coding for C-terminal ends of known glutaminases [9, [15] [16] [17] . The antibodies against renal glutaminase and the pGA104 plasmid were kindly supplied by Professor N. P. Curthoys (Colorado State University, Fort Collins, CO, U.S.A.).
Cell culture and transfection procedure
The Ehrlich ascites tumour cell (EATC) line from the American Type Culture Collection, CCL-77, and its derivatives after transfection were grown in adherent cultures in RPMI-1640 medium (Sigma, St. Louis, MO, U.S.A.) supplemented with 10 % fetal calf serum and antibiotics. The cultures were incubated in a humidified atmosphere at 37 mC with 5 % CO # \95 % air. The culture medium for cell lines containing the neomycin-resistance gene was supplemented with 600 µg\ml G418. The plasmids or the vector control pcDNA3 were transfected in EATCs by lipofection using the lipid Dosper (Boehringer Mannheim, Mannheim, Germany). Cells were selected after growing in complete RPMI-1640 medium containing 600 µg\ml G418 for 2-3 weeks. Following G418 selection, 12 drug-resistant (neo + ) clones (six from each construction transfected) were picked randomly from different plates and studied after expansion. As a control, six neo + clones were picked from EATCs transfected with the pcDNA3 vector lacking the antisense sequences (vectorcontrol cells).
Growth rates
Cells (10% cells\3 ml of medium) were seeded in each well of a sixwell plate and allowed to grow for different times. The trypsintreated cells were counted on a haemocytometer or using a Coulter counter (Coulter, Luton, Beds., U.K.). Cell lines expressing the antisense glutaminase RNA segments, cells transfected with the empty vector, and the parental EATC line were studied. Growth assays were determined by cell enumeration in triplicate for each cell line on every day of culture up to the seventh day. Doubling times and saturation densities were calculated by standard methods. All experiments were repeated at least three times and gave similar results. Cell growth rates were also determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] method described by Mossman with slight modification [18] .
Colony-forming assays
Cells were seeded in triplicate with 250 cells\10-cm dish in complete medium. After 15 days of growth, the cells were fixed and stained with 5 % Giemsa stain, and the grossly visible colonies were counted. All experiments were repeated at least three times and gave similar results.
Blotting assays
Glutaminase protein in total cell extracts of transfected and nontransfected EATCs were subjected to Western-blot analyses. Exponentially growing cells (60-80 % confluence) were pelleted by centrifugation, washed twice with ice-cold PBS, and lysed on ice in RIPA buffer, pH 7.6 [30 mM Hepes, 150 mM NaCl, 1.0 % (v\v) Triton X-100, 0.1 % (w\v) SDS and 1.0 % (w\v) deoxycholic acid], with added proteinase inhibitors, pepstatin A (1.0 µg\ml), leupeptin (10 µg\ml) and 0.2 mM PMSF. Lysates were clarified by centrifugation at 10% g for 10 min at 4 mC. Cell protein (25 µg\lane) was electrophoresed on 10 % SDS\ polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were first incubated with a rabbit antirat renal glutaminase polyclonal antibody and then with a goat anti-rabbit IgG-biotin and avidin-peroxidase antibody ; the anti-rat glutaminase polyclonal antibodies recognize Ehrlich ascites cell glutaminase [10] . Glutaminase bands were detected using diaminobenzidine as a substrate (Sigma).
Northern-blot analyses were performed as described elsewhere [8] using the 0.28 kb rat kidney cDNA segment, mentioned above, as a probe. [19] . For each assay 0.2 ml of cell suspension was used, equivalent to 10' cells ; after 6 min of incubation at 37 mC the reaction was stopped by the addition of 0.5 ml of 0.4 M HCl. The KOH-neutralized mixture was centrifuged at 16 000 g for 5 min. Finally, the glutamate formed was determined by the method according to Lund [20] . To be sure that glutaminase was indeed the assayed enzyme, the results obtained using controls without phosphate were always subtracted. Blanks with samples omitted were also run in parallel.
Glutaminase assay
Phosphate-activated glutaminase activities were determined as follows : harvested cells were washed three times with 0.1 M Tris\HCl, pH 8.0, and suspended in the same buffer for 3 h in order to deplete endogenous substrates. The reaction medium was 0.1 M phosphate, 20 mM glutamine, 20 µg\ml oligomycin and 1.2 µg\ml antimycin A, to prevent mitochondrial glutamate oxidation. Under these conditions glutamine and phosphate are at saturating concentrations
Tumourigenicity assay
To assess tumourigenic capacity, the transfected cDNA glutaminase antisense 0.28AS-2 line was intraperitoneally inoculated in isologous Swiss albino female mice of approx. 25 g in weight. Tumour growth was followed by the daily weighing of each animal [1] . The mice were housed in a controlledenvironment animal facility and allowed free access to food and water.
RESULTS
Growth characteristics and morphology of the glutaminaseantisense-RNA-expressing cells
Transfection with an antisense glutaminase cDNA allows the blockage of gene expression [21] . Ehrlich ascites carcinoma cells growing in itro have been transfected by lipofection, with two different genetic constructions (pcDNA3-1.7 and pcDNA3-0.28), as described in the Materials and methods section. After transfection, 12 different cell clones were selected (six from each construction transfected), and their cell-proliferation rates were determined for each clone by cell enumeration in a Coulter counter. EATC line and cell clones transfected with the pcDNA3 vector without any insert were used as controls. All transfected clones with the antisense glutaminase cDNA segments (1.7 and 0.28 kb) showed a decrease in growth rate. This decrease was more pronounced in cell lines transfected with the shorter 0.28 kb segment of glutaminase antisense cDNA (0.28AS cells). Figure 1 shows the average growth curve of 0.28AS cells, which had a growth rate approx. 50 % less than that of the controls. Colorimetric analyses of tetrazolium-stained cells provide a reliable approximation of cell-proliferation capacity [22, 23] ; the data obtained using the MTT test confirmed the above-expressed results by cell enumeration.
For the following growth-related experiments one of the 0.28AS cell lines, named 0.28AS-2, was selected. The main growth parameters of the 0.28AS-2 line are displayed in Table 1 . The decrease in both proliferation and plating efficiency is noteworthy. This clone displayed a remarkable change in mor- Mice inoculated with 10( control-line cells developed ascitic tumours and died after 16p1 days ; on the contrary, mice inoculated with the same number of antisense-expressing cells did not develop any tumours. Tumour growth in i o was estimated by following the increase in total animal weight daily [1] . When animals were inoculated with a higher number of antisense-glutaminase-transfected cells, they only showed an increase in total weight in the first few days after inoculation due to the presence of ascitic fluid, but no cellular growth was observed. Several days later the ascitic fluid disappeared and the animals recovered their normal weight. None of the animals inoculated with antisense-glutaminase-transfected 0.28AS-2 cells showed any tumours, and they survived for several months.
Phosphate-activated glutaminase activity in antisense-transfected cells
Phosphate-activated glutaminase activities were determined in transfected and non-transfected cells during cell growth. The glutaminase activity profiles versus time obtained for cultured cells in itro were similar to those obtained in i o in intact ascites carcinoma cells growing in mice [8] . Glutaminase activity reached its maximum during the exponential phase of growth, with a subsequent decrease at the stationary phase of growth. Figure 4 shows the glutaminase activities versus time of three 0.28AS lines compared with the controls. The activities were similar in both controls used, but all transfected cells with the 0.28 kb antisensecDNA glutaminase insert showed significant decreases in glutaminase activities. Western-blot analyses of these three 0.28AS lines, using polyclonal anti-rat renal glutaminase antibodies, showed a clear shortage of the glutaminase protein ( Figure 5) , consistent with the shortage in glutaminase activity. Non-significant changes were observed in glutaminase mRNA levels in Northern-blot experiments.
DISCUSSION
The scope of the present work was to confirm the critical role played by phosphate-activated glutaminase in the growth and proliferation of tumour cells [12, 13] . The results presented here demonstrate that the stable expression of heterologous, but highly conserved [16, 17] , rat glutaminase cDNA antisense segments in mouse EATCs leads to a decrease in the proliferation capacity in itro. After screening the behaviour of different stably transfected cell clones, the one named 0.28AS-2 was selected for the most characteristic growth experiments. As a consequence of transfection with cDNA antisense glutaminase, the cells are impaired markedly in their growth and proliferation capacity, since they show a longer doubling time and a decrease in their saturation density and plating efficiency, parameters that are correlated with malignancy. Cells also show marked changes in their morphology.
The transfected cells also display a decrease in the levels of glutaminase protein and activity ; as mentioned above, many experimental data support a direct correlation between glutaminase activity and malignancy in tumours [6, 7] .
These results, taken together, provide evidence that the inhibition of the expression of glutaminase in tumour cells tends to revert their transformed phenotype towards normality. Furthermore, they confirm the relevance of glutamine and phosphate-activated glutaminase, the first step in the glutaminolytic process, which is essential for maintaining the energy and nitrogen metabolism of tumour cells [24] . Recently Spittler et al. [25] have reported similar results using an opposite strategy ; in fact, they have communicated that low glutamine concentrations in the culture medium induce phenotypic and functional differentiation of U937 myelocytic cells.
But, what is perhaps most remarkable is that the 0.28AS-2 cells, which are able to grow in itro, lose their tumourigenic capacity when they are intraperitoneally inoculated into isologous mice. The antisense derivative cells inoculated do not develop any tumours, as the controls do. Control mice (inoculated with parental and vector-control-transfected cells) die 16p1 days after inoculation ; the animals inoculated with cell numbers up to 2.5-fold greater than the controls survive after several months without any apparent disease. These results indicate that phosphate-activated glutaminase is not only essential for tumour growth and progression, but that this enzyme also seems to play a critical role in maintaining the tumourigenic capacity. Furthermore, the present studies provide evidence that the inhibition of glutaminase expression in tumour cells reverts the transformed phenotype in itro, and inhibits their tumourigenicity in i o.
Many attempts have been made in the use of glutamine-related chemotherapy in experimental oncology and in human patients [26, 27] . The usefulness of glutamine analogues [azaserine, azotomycin, DON (6-diazo-5-oxo--norleucine) and acivicin] is very limited [28] in anti-tumour therapy because of their toxicity and the undesirable collateral effects. The use of glutamine clearance by exogenous glutaminase has been utilized in lymphoblastic leukaemia [29] , but it is also limited. These findings open up the possibility of new approaches for the clinical use of glutaminerelated therapy.
